Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23222124 | 0.80 | PPARA (0.38) | CNR1CNR2TP53SMN1; SMN2RAB9A | |
| SCHEMBL507580 | 0.79 | SIRT2 (0.45) | SIRT2CNR1CNR2TP53SMN1; SMN2 | |
| SCHEMBL19203779 | 0.77 | NOTUM (0.40) | SMN1; SMN2RAB9ANPC1PIK3CG | |
| SCHEMBL24258885 | 0.77 | CNR1 (0.31) | HDAC8HDAC2CNR1CNR2TP53 | |
| SCHEMBL24258810 | 0.77 | SIRT2 (0.41) | SIRT2HDAC8HDAC2HDAC1SMN1; SMN2 | |
| SCHEMBL18997069 | 0.76 | PIK3CG (0.34) | TP53SMN1; SMN2RAB9AKLF5NPC1 | |
| SCHEMBL16544514 | 0.76 | SMN1; SMN2 (0.41) | TP53SMN1; SMN2RAB9AKLF5NPC1 | |
| SCHEMBL22352584 | 0.75 | HDAC1 (0.41) | HDAC8HDAC2HDAC1TP53SMN1; SMN2 | |
| SCHEMBL22353808 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL3712081 | 0.73 | PIK3CG (0.36) | TP53SMN1; SMN2RAB9AKLF5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | SIRT2 2746/4885HDAC8 995/4885HDAC2 1068/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | SIRT2 2746/4885HDAC8 995/4885HDAC2 1068/4885 |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | SIRT2 3286/4885HDAC8 2301/4885HDAC2 1719/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | SIRT2 2746/4885HDAC8 995/4885HDAC2 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.